Kornimate/medical-research-clean huggingface dataset:
volatile anesthetic protection of renal transplants 2

Conditions: Delayed Graft Function; Renal Outcome After Kidney Transplantation

Summary: to compare the effect of a sevoflurane based anesthesia versus a propofol based anesthesia on the incidence of dgf in recipients of kidneys of donation after circulatory death (dcd) and donation after brain death (dbd) donors

objective: to compare the effect of a sevoflurane based anaesthesia versus a propofol based anaesthesia on the incidence of delayed graft function in recipients of dcd and dbd donor kidneys. study design: prospective randomized controlled european multicentre clinical trial with two parallel groups study population: patients ≥18 years scheduled for kidney transplantation with a kidney from a dbd or dcd donor intervention: patients will be included and randomised to one of the following groups: group 1 prop (control): propofol: a propofol-remifentanil based anaesthesia. group 2 sevo (intervention): sevoflurane: a sevoflurane-remifentanil based anaesthesia. main study parameters: dgf defined as need of dialysis the first week after transplantation excluding one time dialysis for hyperkalemia acute rejection episodes within the first year after transplantation graft and patient survival gfr at 3 and 12 months pnf defined as a permanent lack of function of the allograft length of hospital stay postoperative complications of all kind kidney biomarkers (urine/plasma) mechanisms of protection/immunomodulation with anestheticanaesthetic agents

Eligibility criteria:
inclusion criteria: * age \> 18 years * written informed consent exclusion criteria: * high immunological risk as determined bij local practice * patients of the abo-incompatible program
effects of glp-1 on chronic heart failure

Conditions: Heart Failure

Summary: the investigators planned to evaluate the effects of liraglutide on left ventricular function in chronic heart failure patients with type 2 diabetes.

heart failure (hf) is a major cause of morbidity and mortality world wide. glucagon-like peptide-1 (glp-1) is an incretin hormone that regulates plasma glucose, and has direct effects on the cardiovascular system. in our previous study, the glp-1 analogue liraglutide could improve left ventricular function in patients with acute myocardial infarction. however, the effects of glp-1 on chronic heart failure patients with type 2 diabetes remain unclear. the aim of this study was to evaluate the effects of liraglutide on left ventricular function in chronic heart failure patients with type 2 diabetes.

Eligibility criteria:
inclusion criteria: * chronic heart failure patients with type 2 diabetes (nyha-class i, ii or iii) were eligible for the study exclusion criteria: * chf (nyha class iv) * type 1 diabetes * hospitalisation due to incompensated heart disease within 30 days prior to randomisation * myocardial infarction within the past 3 months before screening * coronary revascularisation within the past 3 months before screening * atrial fibrillation with ventricular frequency \>100/min in rest * ecg suggestive of malignant ventricular arrhythmia * prolonged qt-interval (\>500 ms) * valvular heart disease * current myocardial or pericardial infection * obstructive hypertrophic cardiomyopathy * cancer unless in complete remission for ≥5 years * acute pancreatitis * compromised kidney function (egfr \<30 ml/min), dialysis or kidney transplantation * history of thyroidea adenoma or carcinoma
a chart review to evaluate the safety and efficacy of mert on subjects with asd

Conditions: Autistic Disorder

Summary: the purpose of this study is to evaluate the safety and efficacy of magnetic eeg/ecg-guided resonance therapy (mert) on subjects with autism spectrum disorder (asd).

this is a retrospective chart review of 200 consecutive charts of subjects ages 2-20 years old seen at the brain treatment center between 2010 and 2015. the review is designed to evaluate the safety and efficacy of magnetic electroencephalogram/electrocardiogram(eeg/ecg)-guided resonance therapy (mert) on subjects with autism spectrum disorder (asd).

Eligibility criteria:
inclusion criteria: 1. must have completed a baseline eeg at the brain treatment center (btc) 2. age between 2 and 20 years old at initial visit 3. must have a diagnosis of asd according to the prevailing standard at that time (i.e., diagnostic and statistical manual-iv (dsm-iv)) (asd group only) 4. must have received magnetic eeg/ecg-guided resonance therapy (mert) for more than (5) sessions (asd group only) exclusion criteria: 5. clinically significant abnormality or clinically significant unstable medical condition during treatment that in the investigator's judgment may have may limited interpretation of the results.

Keywords: autism, chart review, transcranial magnetic stimulation (tms)
high tidal volume induces inflammation in normal lungs

Conditions: Mechanically Ventilated Patients; Normal Lungs

Summary: objective: to compare the effects of a protective versus a conventional ventilatory strategy, on systemic and in lung production of tumor necrosis factor-alpha (tnf-alpha) and interleukin-8 (il-8) in patients without lung disease. hypothesis: high tidal volumes induce inflammation in patients without lung disease design: prospective control-randomized study. patients and setting: twenty patients without lung disease and submitted to mechanical ventilation admitted to one trauma and one general adult intensive care unit of two different university hospitals. interventions: patients were randomized to receive mechanical ventilation either with tidal volume (vt) of 10-12 ml/kg predicted body weight (high vt group) or with vt of 5-7 ml/kg predicted body weight (low vt group) with an o2 inspiratory fraction (fio2) enough to keep arterial oxygen saturation \> 90% with positive end-expiratory pressure (peep) of 5 cmh2o during 12 hours after admission to the study.


Eligibility criteria:
inclusion criteria: 1. age ≥ 16 years; 2. anticipated survival \> 24 hours; 3. need for mechanical ventilation for at least 12 hours and 4. hemodynamic stability (map\>65 mmhg, hr\ 1 ml/kg/h, no catecholamine requirement or fluid challenge). exclusion criteria: 1. history of any lung disease, use of immunosuppressive medication, recent infections, previous thromboembolic disease, recent ventilatory support, and participation in another clinical trial. absence of lung disease was defined by the following clinical criteria: (a) no evidence of respiratory infection (white blood cell count \ 380c, purulent sputum), (b) normal chest roentgenogram, (c) pao2/fio2 ratio \> 300, (d) and a normal clinical respiratory history.

Keywords: ventilator-associated lung injury tumor necrosis factor-alpha interleukin-8 mechanical ventilation low tidal volume ventilation normal lungs
neuroendocrine dysfunction in critically ill pediatric patients

Conditions: Critical Illness

Summary: research studies in adults have shown that certain hormones may be decreased or may not work normally which contributes to how sick a person becomes. the purpose of this project is to study hormones in children. the investigators will look to see if a decrease of certain hormone levels affects how sick a child may become. this study is intended to develop a connection between hormone levels and severity of illness. it is hoped that the information gathered will help develop further studies that may more clearly explain the role of hormones in critically ill children and possibly the introduction of hormone replacement in critical illness.

neuroendocrine dysfunction is an abnormality in the production or release of certain hormones. studies completed in adult patients have shown abnormal hormone levels in critical illness can contribute to how long patients stay in the intensive care unit, how severe their illness is and whether or not they survive. in children hormones are produced differently and have different functions. depending on the particular illness in question hormonal dysfunction may have grave clinical consequences. thus far, there have been few studies that have examined neuroendocrine dysfunction in children. the aim of our study is to identify the common hormone responses in children, and to identify any connection between hormone levels and outcomes (likelihood of child staying in the intensive care unit for multiple days, etc.). to explore these aims we will draw blood from all critically ill patients admitted to the pediatric intensive care unit (picu) and check various hormone levels. only those patients who require blood samples as part of their admission will have blood tests for certain hormone levels. no change will be made from established standard of care for a patient's particular critical illness. the study is designed to examine hormone responses to critical illness and identify a connection between hormone levels and severity of illness. based on these lab values we intend to lay a foundation for further studies that may more clearly explain the role of hormones in critically ill children, and possibly the introduction of hormone replacement in critical illness.

Eligibility criteria:
inclusion criteria: * all patients, birth - 18 years of age * admitted to the pediatric intensive care unit requiring blood to be drawn as part of medical management consistent with "standard of care". exclusion criteria: * elective post-operative surgical patients. * pre-existing/known neuroendocrine disorder including, but not limited to, disorders of the hypothalamus, pituitary, adrenal, or thyroid gland. * patients being treated with or having a recent history of taking anti-psychotic medications (e.g. ingestion). * patients whose laboratory specimens have already been drawn prior to admission (emergency room or another facility) and who do not require further blood draws for medical management within a 12 hour window.

Keywords: pediatric intensive care neuroendocrine dysfunction
crm and fusion beats: effects of progressive fusion on intra-left ventricular mechanical function

Conditions: Cardiomyopathy

Summary: this study is looking at cardiac rhythm management (crm) and fusion beats in patients who have a pacemaker or implantable cardioverter-defibrillator (icd), to determine if there is a correlation between the time between the contraction of the upper chambers of the heart (atrium) and the lower chambers of the heart, (ventricle) and heart function. some studies of people with pacemakers have been done to determine if shortening the time of contraction between the atrium and ventricle could benefit the function of the left ventricle. these studies have shown that there is no benefit in heart function.there have been other studies which have shown that chronic pacing of the right ventricle, especially with the lead placed at the tip of the right ventricle, can lead to a decrease in the function of the left ventricle and congestive heart failure. in some patients long term pacing of the right ventricle has also been associated with a reduction in the ability of the left ventricle to pump blood. this is know as a reduced left ventricular ejection fraction, which can be documented by an echocardiogram. this study proposes to evaluate the acute effects of progressive paced fusion beats on the left ventricle to answer the question whether there is an delay between the atrium and ventricle that is "too long" or "too short".


Eligibility criteria:
inclusion criteria: * dual chamber pacemaker or icd device * left ventrical ejection fraction (lvef) 40% or less * sinus rhythm with intact atrioventricular conduction with a pr interval greater than 200 msec qrs less than 120 msec * pacing right ventricle lead in the right ventricular apex (rva), system implanted within 6 weeks or chronically implanted system with histograms showing 20% or less right ventricle pacing exclusion criteria: * lvef greater than 40%, * any rhythm other than sinus rhythm * second degree or higher atrioventricular block * native heart rate less than 40 beats per minute or greater than 90 beats per minute * left ventricle or chronic sinus lead in non-rva location * chronically implanted system with greater than 20% right ventricle pacing
egg protein hydrolysate and vascular function

Conditions: Arterial Stiffness; Dietary Modification; Impaired Glucose Tolerance; Type 2 Diabetes Mellitus

Summary: the incidence of type 2 diabetes mellitus (t2dm) is rapidly growing. patients with t2dm are at increased risk of developing long term micro- and macrovascular complications. subjects with impaired glucose tolerance (igt) show increased blood glucose levels after an oral glucose load. these subjects have a markedly increased risk of later t2dm development. t2dm development can be prevented or delayed by lifestyle modifications. to support lifestyle changes and reduce the risk of t2dm development, foods containing functional ingredients are being developed. an interesting functional ingredient is protein hydrolysate. an egg protein hydrolysate has been experimentally shown to improve endothelial function, to inhibit plasma angiotensin converting enzyme (ace) and to reduce blood pressure in rats. egg protein hydrolysate could thus be a interesting ingredient to treat the cardiovascular dysfunction associated with t2dm. in the present study, the effects of egg protein hydrolysate will be evaluated in subjects with overweight or moderate obesity and igt or t2dm.


Eligibility criteria:
inclusion criteria: * age between 18 and 70 years; * male and female; * body mass index (bmi) between 25-35 kg/m2; * diagnosed t2dm (subjects are allowed to use oral antidiabetics and/or to be on a diabetes diet) or impaired glucose tolerance (defined as blood glucose \> 7.8 mmol/l and \< 11.0 mmol/l, two hours after ingesting 75 gram glucose in 150 ml water) exclusion criteria: * known allergy to (chicken) egg proteins; * active cardiovascular diseases like congestive heart failure or recent (\< 6 months) event (acute myocardial infarction, cerebral vascular incident); * severe medical conditions related to the intestine that might interfere with the study such as inflammatory bowel disease and celiac disease; * the use of insulin; * the use of medication such as antihypertensives, statins or drugs that change gastric motility or emptying; * abuse of drugs or alcohol (\> 21 units per week); * pregnant or breast-feeding women; * current smoker; * having donated blood at the blood bank within a period of 8 weeks prior to the start of the study

Keywords: egg protein hydrolysate
intense regulated pulsed light vs standard of care for the treatment of meibomian gland dysfunction

Conditions: Meibomian Gland Dysfunction

Summary: this study is to evaluate the effectiveness of e\>eye intense regulated pulsed light (irpl) treatment compared to the current standard of care using a daily warm compress

e-eye is a medical device that has been specifically designed for treating dry eye syndrome due to meibomian gland dysfunction (mgd). this study is a prospective, single centred, interventional, randomized study assessing the efficacy and safety of e\>eye in the management of mgd (3 applications on days 0, 15 and 45, with a follow up 1 month later) compared to daily use of a warm compress over a period of 75 days. the study will monitor the change in symptoms and signs of dry eye at each visit.)

Eligibility criteria:
inclusion criteria: * willing and able to provide informed consent and participate in the required study visit * subjects determined to have signs and symptoms of evaporative dry eye disease due to mgd, defined by the following: * osdi score \>13 and * nitbut \<= 10sec exclusion criteria: * no use of warm compresses, intense pulsed light therapy or other lid warming treatment in the past 6 months * patients with greater 75% meibomian gland loss * presence of ocular pathology or systemic conditions other than previously diagnosed moderate or severe chronic dry eye and/or sjogren's syndrome, that in the investigator's judgment may affect the testing for, or diagnosis of, dry eye if present * use of prescribed ocular topical medication (e.g., anti-hypertensive, steroid, cyclosporin a, antibiotic) within the last 24 hours * artificial tear usage within 2 hours prior to study testing * other invasive ocular diagnostic testing within 2 hours prior to study testing * eye makeup present on the eye lid within 10 minutes prior to study testing
longitudinal care: smoking reduction to aid cessation

Conditions: Chronic Diseases

Summary: the purpose of this study is to determine whether an extended care treatment model lasting over a year will increase long-term smoking cessation rates compared to the standard 8 week treatment of care.

objective the objective of this project is to conduct a randomized controlled trial to compare 1) an extended quality care smoking cessation treatment delivered over a one-year period (eqc) to 2) quality care smoking cessation treatment delivered over an 8 week period (qc) to determine if eqc improves prolonged smoking abstinence. research design/methodology 500 smokers who are interested in quitting will be enrolled and randomly assigned to the eqc or qc groups. both groups will initially receive a state-of-the-science smoking cessation intervention including behavioral and pharmacological components, delivered by a combination of in-person and telephone care. eqc participants who fail to quit, reduce but do not quit, or relapse will receive intensive treatment over the ensuing 12 months that encourages repeat quit attempts and smoking reduction if they are not to quit. we propose reduction as an intermediate goal in lc because this may increase the likelihood of cessation, increase self-efficacy and keep smokers and clinicians engaged. reduction treatment will include behavioral treatment and nicotine replacement. qc participants will only receive occasional prompts to quit. the primary endpoint will be 6m of abstinence measured 18m after enrollment. secondary endpoints will include point prevalent abstinence, smoking reduction, self-efficacy and satisfaction. we will also collect qualitative data from successful abstainers and reducers about decision making processes and intervention experiences. clinical significance this project will address the potential role of smoking reduction in the treatment menu for smokers interested in quitting. this project examines mechanisms, methods and a "real world" application for reducing toxin exposure.

Eligibility criteria:
inclusion criteria: * age 18-80 * current and regular smoker 5 or more cigarettes per day * interested in making a quit attempt in the next 14 days * personal phone available exclusion criteria: * pregnancy or plans to become pregnant in the next year * cannot speak english * not a union member or employee of specified worksite or immediate family member * member of household is currently enrolled in the study * not willing to comply with study protocol

Keywords: smoking cessation smoking reduction nicotine replacement therapy
internet-delivered cbt for children with functional gastrointestinal disorders - an open pilot study

Conditions: Functional Gastrointestinal Disorders

Summary: this pilot-study aims to evaluate the effect size and feasibility of internet-delivered cognitive behavior therapy (icbt) for children (age 8-12 years) with pain-predominant functional gastrointestinal disorders (e.g. irritable bowel syndrome, functional abdominal pain and functional dyspepsia according to the rome iii criteria). the main component investigated in this study is exposure for gastrointestinal symptoms and for feared stimuli and situations. children will participate along with one of their parents in the treatment. the parents will also receive specific modules with information on how to support their child in the treatment.


Eligibility criteria:
inclusion criteria: * children between 8-12 years (until their 13th birthday) who have been diagnosed with any of the diagnoses irritable bowel syndrome, functional dyspepsia or functional abdominal pain according to the rome iii criteria. * any psychopharmacological medication should be stable since 1 month. * parents and children need to master swedish, have access to a computer with internet access, and be willing to participate in 10 weeks of treatment with homework. exclusion criteria: * simultaneous presence of serious somatic disease and / or if the child meets the criteria for other organic disease which better explains the symptoms. * psychiatric or social problems that are considered serious and in need of a more intense treatment than icbt leads to exclusion. children with higher school absenteeism than 40% will not be included. neither will children who have an ongoing psychological treatment be included,
treatment and control of atopic dermatitis with 0.03% tacrolimus ointment

Conditions: Dermatitis, Atopic

Summary: a long-term 0.03% tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat active lesions of atopic dermatitis, and prevent, delay, and reduce flares.


Eligibility criteria:
inclusion criteria: * male or female patient of any ethnic group * patient was at least 2-15 years old and suffered from mild to severe atopic dermatitis (rajka/langeland score of at least 3) exclusion criteria: * patient had a genetic epidermal barrier defect such as netherton's syndrome or generalised erythroderma * patient had a clinically significant skin infection on the affected (and to be treated) area

Keywords: dermatitis, atopic tacrolimus child treatment outcomes